You're changing your argument. You went from "everything being in flux" the last seventeen months, to "the internal state of the CNS pharma industry." The latter should not be the cause of Corx's difficulty in forming an RD partnership (for indications with no current treatment, and similarly, no competition).
Market Data 
Markets 
AI
